Q-omics provides the consensus-scored OXCT2P1 profile across patient tissues and cancer cell-line models. OXCT2P1 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, OXCT2P1 is differentially expressed in 9, with the highest sampling consensus in THCA. Additionally, OXCT2P1 RNA expression shows 11,830 significant gene co-expression associations, with the highest sampling consensus in PAAD. Together, these results highlight MESO, THCA, and PAAD as cancer lineages where OXCT2P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OXCT2P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OXCT2P1 survival associations across molecular data types. OXCT2P1 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OXCT2P1 RNA expression–survival associations across cancer types. High OXCT2P1 expression shows unfavorable associations in MESO, UVM, ACC, THCA, LAML and COAD. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for OXCT2P1 RNA expression.
This table summarizes OXCT2P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for OXCT2P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OXCT2P1 shows lower tumor expression in THCA, UCEC, KICH and PRAD and higher tumor expression in LIHC and HNSC. The THCA box plot shows higher OXCT2P1 RNA expression in normal versus tumor tissue (log2 FC = −0.836, t-test p < 0.001).
This table shows molecular features associated with OXCT2P1 in patient tissues and cancer cell lines. In patient samples, OXCT2P1 shows the broadest associations at the RNA and protein expression levels, with PAAD recurring as the lineage with the largest associated feature set.
